Derek Miller - 02 May 2023 Form 4 Insider Report for AMGEN INC (AMGN)

Role: SVP, Human Resources
Signature: /s/ Derek Miller
Issuer symbol: AMGN
Transactions as of: 02 May 2023
Net transactions value: -$13,450
Form type: 4
Filing time: 04 May 2023, 20:31:27 UTC
Previous filing: 02 May 2023
Next filing: 09 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMGN	Common Stock	Award	$0	+1,101	+17%	$0.000000	7,661	02 May 2023	Direct	F1
transaction	AMGN	Common Stock	Tax liability	$13,450	-57	-0.74%	$235.97	7,604	03 May 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMGN	Nqso (Right to Buy)	Award	$0	+9,316		$0.000000	9,316	02 May 2023	Common Stock	9,316	$235.97	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.
F2	These shares include the following RSUs granted under the Company's equity plans: 114 RSUs which will vest in installments of 56 on 5/5/2023 and 58 on 5/5/2024; 974 RSUs which will vest in installments of 479 on 11/2/2023 and 495 on 11/2/2024; 201 RSUs which will vest in installments of 99 on 4/30/2024 and 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026.; and 1,101 RSUs which will vest in two installments of 363 on 5/2/2025 and 5/2/2026, and 375 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3	These shares include 81 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4	These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.